MAPT and Alzheimer disease: Studies using AD biomarkers have reported that cognitive decline in AD patients with psychosis correlates with increased tau retention on positron emission tomography (PET) and elevated cerebrospinal fluid (CSF) total tau levels (Koppel et al., 2013).